At a glance
ClinicalIndex Comparison RecordN/ACompleted· 933 enrolled
Drug / intervention
Bimatoprost 0.01% ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
In Brief
An observational study evaluating Bimatoprost 0.01% ophthalmic solution for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 933 participants across 1 site.
Detailed Summary
This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedApr 2012
Primary CompletionSep 2012
TodayJul 2026
First PostedApr 2, 2012
Enrollment StartOct 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.3 years ago
Interventions
Bimatoprost 0.01% ophthalmic solutiondrug
Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.